VEGF Overexpression is Associated with Optic Nerve Involvement and Differentiation of Retinoblastoma: A PRISMA-compliant Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Dec 22

PMID 30572521

Citations 3

Authors

Qizheng Wu

Xiao Sun

Guangying Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of cancer. Although numerous studies have investigated the association between VEGF expression and pathogenesis of retinoblastoma, the results remained inconsistent. To illuminate the association, we performed a meta-analysis study.

Methods: According to the PRISMA guideline, eligible studies were searched in the Medicine, Embase, Web of Science, Chinese National Knowledge Infrastructure, and Wanfang databases. Stata 14.0 software was used to calculate the relevant statistical parameters.

Results: Seventeen studies with 296 controls and 470 patients with retinoblastoma were included from 17 eligible literatures. Overall, significant association between VEGF overexpression and susceptibility of retinoblastoma was observed in Chinese population (odds ratio [OR] = 21.67, 95% confidence interval [CI] = 13.96-33.62). Subgroup analysis based on control sample type showed that VEGF overexpression was significantly associated with the risk of retinoblastoma (Normal retina tissue, OR = 23.97, 95% CI = 9.67-59.42; retinoblastoma adjacent tissue, OR = 20.85, 95% CI = 12.64-34.37). Significant associations of VEGF overexpression with optic nerve involvement and differentiation of retinoblastoma were found (Optic nerve involvement, OR = 6.90, 95% CI = 4.01-11.88; Differentiation, OR = 0.18, 95% CI = 0.12-0.28). In addition, only 1 study was included to analyze the role of VEGF protein expression in the prognosis of retinoblastoma, and the result showed that VEGF expression was significantly associated with the prognosis of retinoblastoma, which should be verified in the future studies.

Conclusions: Our findings demonstrated that VEGF overexpression was significantly associated with the risk of retinoblastoma. Besides, the results suggested that VEGF overexpression might have a crucial effect on the optic nerve involvement and differentiation of retinoblastoma.

Citing Articles

Dynamic contrast-enhanced magnetic resonance imaging assessment of residual tumor angiogenesis after insufficient microwave ablation and donafenib adjuvant therapy.

Ren Z, Feng G, Li B, Zhang C, Du Y Sci Rep. 2024; 14(1):4557.

PMID: 38402352 PMC: 10894284. DOI: 10.1038/s41598-024-55416-8.

2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma.

Ren R, Gao L, Li G, Wang S, Zhao Y, Wang H Front Pharmacol. 2023; 14:1177282.

PMID: 37089961 PMC: 10119426. DOI: 10.3389/fphar.2023.1177282.

Liu Z, Huang Y, Zhang F, Tang H, Wang Y Ann Transl Med. 2020; 8(21):1451.

PMID: 33313196 PMC: 7723560. DOI: 10.21037/atm-20-6009.

References

Lee S, Kim D, Cho J, Koh J, Yoon Y . Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol. 2008; 126(7):953-8. DOI: 10.1001/archopht.126.7.953. View

Storkebaum E, Ruiz de Almodovar C, Meens M, Zacchigna S, Mazzone M, Vanhoutte G . Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. Circulation. 2010; 122(3):273-81. DOI: 10.1161/CIRCULATIONAHA.109.929364. View

Abramson D, FRANK C, Susman M, Whalen M, Dunkel I, Boyd 3rd N . Presenting signs of retinoblastoma. J Pediatr. 1998; 132(3 Pt 1):505-8. DOI: 10.1016/s0022-3476(98)70028-9. View

Sangwan M, McCurdy S, Livne-Bar I, Ahmad M, Wrana J, Chen D . Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene. 2012; 31(48):5019-28. PMC: 4977187. DOI: 10.1038/onc.2011.654. View

Shields C, Fulco E, Arias J, Alarcon C, Pellegrini M, Rishi P . Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond). 2012; 27(2):253-64. PMC: 3574237. DOI: 10.1038/eye.2012.175. View

Radhakrishnan V, Kashyap S, Singh L, Bakhshi S . VEGF expression in residual tumor cells in orbital retinoblastoma (IRSS stage III) treated with NACT: a prospective study. Pediatr Blood Cancer. 2011; 59(3):567-9. DOI: 10.1002/pbc.24009. View

Theriault B, Dimaras H, Gallie B, Corson T . The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol. 2014; 42(1):33-52. PMC: 3896868. DOI: 10.1111/ceo.12132. View

Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M . Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000; 6(2):572-7. View

Hermansson M, Nister M, Betsholtz C, Heldin C, Westermark B, Funa K . Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A. 1988; 85(20):7748-52. PMC: 282270. DOI: 10.1073/pnas.85.20.7748. View

10.

Youssef N, Said A . Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. Int J Clin Exp Pathol. 2014; 7(9):5725-37. PMC: 4203185. View

11.

Dyer M, Rodriguez-Galindo C, Wilson M . Use of preclinical models to improve treatment of retinoblastoma. PLoS Med. 2005; 2(10):e332. PMC: 1261510. DOI: 10.1371/journal.pmed.0020332. View

12.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

13.

Lohmann D, Brandt B, HOPPING W, Passarge E, Horsthemke B . Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma. Hum Genet. 1994; 94(4):349-54. DOI: 10.1007/BF00201591. View

14.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

15.

Dalgard C, Gonzalez M, deNiro J, OBrien J . Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci. 2009; 50(10):4542-51. DOI: 10.1167/iovs.09-3520. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

17.

Baud O, Cormier-Daire V, Lyonnet S, Desjardins L, Turleau C, Doz F . Dysmorphic phenotype and neurological impairment in 22 retinoblastoma patients with constitutional cytogenetic 13q deletion. Clin Genet. 1999; 55(6):478-82. DOI: 10.1034/j.1399-0004.1999.550614.x. View

18.

Smith B, Smith G, Carter D, DiGiovanna M, Kasowitz K, Sasaki C . Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001; 127(7):780-5. View

19.

Nemeth K, Federico S, Carcaboso A, Shen Y, Schaiquevich P, Zhang J . Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer. 2010; 117(2):421-34. PMC: 3000447. DOI: 10.1002/cncr.25574. View

20.

Rushlow D, Mol B, Kennett J, Yee S, Pajovic S, Theriault B . Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013; 14(4):327-34. DOI: 10.1016/S1470-2045(13)70045-7. View